There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…
Human immunodeficiency virus (HIV) is treatment is typically initiated with daily administration of costly yet highly effective antiretroviral therapies from multiple drug classes in order to…
Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursement on its head by introducing indication-…
Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…
Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T…
MARKET OUTLOOK Bipolar disorder (BPD) is a debilitating psychiatric illness that is increasingly considered to be a spectrum disorder. Patients experience symptoms ranging in severity from…
Faced with the financial pressures of reimbursing a robust pipeline of new and expensive cancer therapies, U.S. managed care organizations (MCOs) are increasing their focus on managing the…
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…
MARKET OUTLOOKLow testosterone is a condition characterized by impaired spermatogenesis and low serum testosterone. In adult men, low testosterone can be caused by intrinsic abnormalities…
Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription…
Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…
Introduction: This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers’ and…
For the estimated 3 million people in the United States who have Alzheimer’s disease (AD), approved treatment is limited to five procognitive symptomatic therapies (e.g., donepezil, memantine)…
Based on DRG’s gold-standard Epidemiology data, the Interactive Patient Flow Model provides insight into the epidemiology of HCV for five different treatment scenarios.With the introduction of…
